The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Abroad (travel likely)RecruitingPHASE2

Conditions

Large B-cell Lymphoma · TP53

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
WEI XU · xuwei10000@hotmail.com · 86-25-68302182

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Diffuse Large B-cell Lymphoma · Relapsed and Refractory

Abroad (travel likely)RecruitingPHASE2

Xiamen, China

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Large B-cell Lymphoma · Lymphoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T

Large B-cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Grade 3b Follicular Lymphoma · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Abroad (travel likely)RecruitingPHASE1, PHASE2

Minneapolis, United States · Columbus, United States